Pharmaceuticals
Advent acquires China's largest medical capsule maker
Advent International has acquired a majority stake in Guangsheng Medicinal Capsule (GS Capsule), the largest medical capsule maker in China, for an undisclosed sum.
2022 preview: Healthcare
Healthcare’s high-cost, rapidly digitizing profile will persist regardless of how COVID-19 plays out in the coming years. China appears set for consolidation, including in biotech
China's Avistone Pharmaceuticals raises $200m
Avistone Pharmaceuticals, a Beijing biotech company focused on precision oncology therapeutics has raised more than $200 million in a Series A funding round led by Vivo Capital.
Biotech player CANbridge drops on debut after $87m HK IPO
CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses on treatments for cancer and rare diseases, lost 27% in value on its Hong Kong trading debut following a HK$685.1 million ($87.8 million) IPO.
China’s ABclonal Technology raises $189m
Chinese life science research and diagnostic reagents provider ABclonal Technology has raised a RMB1.2 billion ($189 million) Series D round featuring Sequoia Capital China.
Singapore's Aura acquires Australia vaccination player
Singapore-based Aura Private Equity has acquired a majority stake in Australian Vaccine Services (AVS), a leading provider of corporate flu vaccinations.
Vision Fund joins $300m round for China vaccine developer
SoftBank Vision Fund 2 and 5Y Capital have led a $300 million Series C extension for Suzhou Abogen Biosciences, a Chinese vaccine developer focused on mRNA products, including one for COVID-19.
Qiming leads $40m round for Allorion Therapeutics
China and US-based precision medicine company Allorion Therapeutics has raised a $40 million Series A round led by Qiming Venture Partners.
China biotech IPOs in Hong Kong to stay strong - AVCJ Forum
The frenzy for Chinese biotech developers listing in Hong Kong is expected to continue well into 2022, industry participants told the AVCJ Private Equity & Venture Forum.
China ocular drugs developer raises $63m
China’s Neurophth Biotechnology, a gene therapy developer for ocular diseases, has raised a RMB400 million ($63 million) Series C round led by SDIC China Merchants Investment and Sequoia Capital China.
GL Capital leads $125m round for Hzymes Biotechnology
Wuhan-based Hzymes Biotechnology, a specialized enzymes developer, has raised RMB800 million ($125 million) in Series C funding led by healthcare specialist GL Capital
China CRO Tripod raises $156m
Tripod Preclinical Research Laboratories, a China-based contract research organization (CRO) based in Nanjing, has raised RMB1 billion ($156 million) led by Ruihua Capital, Lilly Asia Ventures (LAV) and GL Ventures.
Blackstone buys Australia clinical trials specialist
The Blackstone Group has acquired Nucleus Network, which claims to be Australia’s largest phase-one clinical trials provider, for an undisclosed sum. It provides an exit for local GP Crescent Capital Partners.
Deal focus: Biotech gets more cerebral
As opportunity appears to plateau in the most popular biotech segments, brain health could come to the fore. Neurology specialist Cerecin is tracking greater interest amid industry traction in the lab
Pencarrow makes New Zealand clinical research investments
Pencarrow Private Equity has invested in two of New Zealand’s leading clinical research companies, combining them into a single entity in which it holds a 52.3% stake.
Korea GPs invest $40m in Singapore biotech player
A group of Korean private equity investors has committed $40 million in funding to Cerecin, a Singapore-based biotech developer focused on neurotherapeutics.
PE-backed Abbisko trades up after $225m Hong Kong IPO
China-based oncology drug developer Abbisko Therapeutics gained nearly 10% on its Hong Kong trading debut following a HK$1.75 billion ($225 million) IPO.
China biotech start-up LianBio files for US IPO
LianBio, a two-year-old Chinese biotech start-up incubated by life sciences investor Perceptive Advisors, has filed for a US IPO.
China biotech: Going global
A gradual shift in focus from sourcing assets from overseas for application in China to bringing China-made treatments to the world is challenging the notion of what constitutes a local biotech start-up
LAV leads $50m Series B for China's Lynk Pharma
Lilly Asia Ventures (LAV) has led a $50 million Series B round for Lynk Pharmaceuticals, a China-based drug developer that focuses on small-molecule treatments for autoimmune disease, inflammation, and cancer.
China cancer treatment specialist Ionova raises $100m
Tsing Song Capital, a Chinese healthcare-focused private equity firm, has led a $100 million round for Ionova Life Science, a local biotech player specializing in cancer treatments.
China vaccine developer Abogen raises $700m
Suzhou Abogen Biosciences, a Chinese vaccine developer targeting COVID-19, has raised $700 million in Series C funding featuring Temasek Holdings, Loyal Valley Capital, and Lilly Asia Ventures.
Boyu, Janchor back China medical finance start-up
MediTrust Health, China-based healthcare payments and insurance platform, has raised RMB2 billion ($309 million) in Series C funding led by Boyu Capital and Janchor Partners.
China's Miaoshou Doctor raises $231m Series F
Beijing Yuanxin Technology, operator of China-based online healthcare services platform Miaoshou Doctor, has raised RMB1.5 billion ($231 million) in Series F funding featuring Sequoia Capital China.